Search for content, post, videos

Genmab and Seattle Genetics present new data

Jan van de Winkel
Genmab and Seattle Genetics has presented data from the innovaTV 204 phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer. Patients had previously received a doublet chemotherapy and, if elig
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.